Praliciguat, a Clinical-stage sGC Stimulator, Improved Insulin Sensitivity, Lipid Tolerance and Energy Utilization in a Diet-induced Obesity Mouse Model
9th International Conference on cGMP (2019)
Data from this preclinical study suggest that praliciguat may have positive effects on key metabolic parameters.
Praliciguat reduced postprandial circulating triglycerides in a mouse model of type 2 diabetes, suggesting improved lipid handling
Metabolic effects of praliciguat in preclinical studies
Juli Jones, Cyclerion’s head of pharmacology and presenting author at the 9th International Conference on cGMP, shares more about a preclinical study that demonstrated an association between treatment with praliciguat and improved insulin sensitivity, lower triglycerides, and increased fat oxidation.